ZBH - Zimmer Biomet Holdings: Moving Along
2024-05-17 15:19:41 ET
Summary
- Zimmer Biomet Holdings, Inc.'s growth has been modest, as investors are concerned about the rise of GLP-1 drugs, raising concerns about future growth.
- The company's revenue stagnated after spinning off its dental and spine operations, but recently has seen moderately solid growth.
- Zimmer's first quarter results were soft, creating pressure on the outlook for the year and increasing the risk of meeting the full-year guidance.
In the fall of last year, I believed that there were still many questions to be answered after a solid year so far in the case of Zimmer Biomet Holdings, Inc. ( ZBH ) . Amidst a flattish share price (for years) and modest organic growth, the company has grown into its valuation, yet at the same time, it was the rise of GLP-1 drugs which raised concerns about future growth....
Zimmer Biomet Holdings: Moving Along